Skip to content
Study details
Enrolling now

Nicotinamide Riboside for Arterial Stiffness and High Blood Pressure in Kidney Disease

University of Colorado, Denver
NCT IDNCT04040959ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

118

Study length

about 4.8 years

Ages

35–80

Locations

1 site in CO

About this study

Researchers are testing whether nicotinamide riboside can help reduce arterial stiffness and high blood pressure in people with kidney disease. The trial will give participants either nicotinamide riboside or a placebo (inactive pill) for 3 months. Researchers will measure the stiffness of their arteries, blood pressure, and levels of certain substances related to inflammation and oxidative stress.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take Nicotinamide riboside
PhasePhase 2
DrugNicotinamide riboside
Primary goalcarotid-femoral pulse wave velocity

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low13%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Endpoints

Primary: carotid-femoral pulse wave velocity

Secondary: Systolic blood pressure

Body systems

Renal